Tresiba (Insulin Degludec) Monitoring for Adolescents Aged 12 to 17

Why Monitoring Differs for Adolescents on Degludec

Adolescents between 12 and 17 face a unique metabolic environment that changes the way clinicians should track basal insulin therapy. Puberty drives insulin resistance through growth hormone surges, and this resistance can shift rapidly over months. Degludec's 25-hour half-life and steady-state pharmacokinetics offer less day-to-day variability than insulin glargine U100, but that same ultra-long action profile means dose adjustments take longer to manifest.

The FDA approved Tresiba for pediatric patients aged 1 year and older in 2019, based on the BEGIN YOUNG 1 trial that enrolled children and adolescents with type 1 diabetes [1]. That trial demonstrated comparable HbA1c reduction to insulin detemir with a lower rate of hypoglycemia. The DEVOTE cardiovascular outcomes trial (N=7,637) established degludec's cardiovascular safety and showed a 40% reduction in severe hypoglycemia compared to glargine U100, with a 53% reduction in nocturnal severe hypoglycemia [2]. While DEVOTE enrolled adults, these hypoglycemia findings inform pediatric practice because nocturnal lows remain one of the most feared complications in adolescent diabetes management.

The 2024 ADA Standards of Care recommend individualized monitoring for youth on basal insulin, with specific attention to developmental stage, school schedules, and psychosocial factors [3]. Adolescents are not small adults. Their monitoring plans must account for hormonal fluctuations, adherence challenges tied to autonomy development, and the intersection of diabetes management with peer dynamics and mental health.

HbA1c and Glycemic Targets

The ADA recommends an HbA1c target of <7.0% for most children and adolescents with type 1 diabetes, with individualization based on hypoglycemia risk, disease duration, and patient preference [3]. Check HbA1c every 3 months. This cadence matters more in adolescence than in stable adult patients because pubertal insulin resistance can cause HbA1c drift within weeks.

A rising HbA1c between visits does not always mean nonadherence. Growth hormone peaks during mid-puberty (Tanner stages 3 to 4) can increase insulin requirements by 30 to 50% compared to pre-pubertal needs [4]. Before attributing worsening glycemia to behavioral factors, clinicians should assess Tanner stage and recent growth velocity. An adolescent growing 8 cm per year at Tanner stage 3 may simply need a dose increase of 0.1 to 0.2 units/kg.

Point-of-care HbA1c at every quarterly visit allows real-time discussion. Waiting for lab results delays the conversation. If the clinic does not offer point-of-care testing, order the lab draw 5 to 7 days before the scheduled visit so results are available during the appointment.

For adolescents on degludec specifically, the flat pharmacokinetic profile means that fasting glucose trends are a more reliable signal of basal dose adequacy than they are with peakier basal insulins. A fasting glucose consistently above 130 mg/dL on three consecutive mornings, with no overnight lows on CGM, signals a need for a 1 to 2 unit dose increase. Wait a minimum of 3 days before making additional adjustments, because degludec's steady state shifts gradually.

Continuous Glucose Monitoring Protocol

CGM use should be standard for adolescents on insulin degludec. The International Consensus on Time in Range established a target of greater than 70% time in range (70 to 180 mg/dL), with less than 4% time below 70 mg/dL and less than 1% below 54 mg/dL [5]. These targets apply to adolescents, though the ADA acknowledges that less stringent goals may be appropriate during periods of rapid growth or significant psychosocial stress.

Review the ambulatory glucose profile (AGP) at every visit. Focus on three specific patterns:

Overnight stability. Degludec's flat profile should produce a relatively stable overnight trace. If the AGP shows a consistent rise between 2:00 AM and 6:00 AM (dawn phenomenon), the basal dose may be insufficient. If it shows a dip between midnight and 3:00 AM, the dose may be too high. Because degludec cannot be "split" the way twice-daily detemir can, the only lever is the total daily dose.

Post-meal return to baseline. While this is primarily a bolus insulin issue, an adolescent whose glucose never returns to baseline between meals may have an inadequate basal dose masquerading as bolus underdosing.

Coefficient of variation (CV). A CV above 36% suggests unstable glycemia. In one analysis of pediatric CGM data published in Diabetes Technology & Therapeutics, adolescents had higher glucose variability than younger children even on the same insulin regimen, driven by irregular meal timing and activity patterns [6]. Degludec's lower day-to-day variability (within-patient CV of 20% vs. 37% for glargine U100 in pharmacokinetic studies) can partially mitigate this, but the clinician still needs to evaluate whether glycemic instability originates from basal coverage gaps or lifestyle factors.

The ISPAD 2022 Clinical Practice Consensus Guidelines recommend that clinicians review CGM data remotely between visits for adolescents with HbA1c above target or recurrent hypoglycemia [7]. A 2-week data download reviewed via telehealth at the midpoint between quarterly visits can catch dose inadequacy before it compounds into a 0.5% HbA1c rise.

Hypoglycemia Screening

Hypoglycemia monitoring in adolescents on degludec involves both CGM-based detection and structured questioning. The DEVOTE trial showed a 53% lower rate of nocturnal severe hypoglycemia with degludec versus glargine U100 (rate ratio 0.47, 95% CI 0.31 to 0.73) [2]. This is a meaningful clinical advantage, but it does not eliminate hypoglycemia risk.

Screen at every visit using a structured hypoglycemia questionnaire. Ask specifically about:

• Episodes requiring help from another person in the past 3 months
• Overnight lows detected by CGM alarm (even if the patient self-treated)
• Events during or after sports practice or physical education class
• Episodes associated with alcohol use (a conversation that becomes relevant by ages 15 to 17 in clinical practice)

Impaired hypoglycemia awareness develops in adolescents just as it does in adults. The Clarke or Gold questionnaire, validated in adults, can be adapted for adolescents aged 15 and older [8]. For younger adolescents, ask parents or guardians about behavioral signs of low glucose that the patient may not recognize: irritability, sudden fatigue during activities, or difficulty concentrating during homework.

CGM low-glucose alerts should be set at 70 mg/dL with an urgent alarm at 55 mg/dL. Review alert fatigue at every visit. An adolescent who silences every alarm has effectively turned off their safety net. If alert fatigue is present, consider widening the predictive low alert to 20 minutes rather than the default 30 minutes, reducing unnecessary early warnings.

Growth Velocity and Pubertal Development Tracking

Measure height and weight at every visit and plot on age-appropriate growth charts. This is not optional for any adolescent on insulin therapy. Insulin is an anabolic hormone, and both excess and insufficient dosing can affect growth patterns.

The Hvidoere Study Group demonstrated that pediatric patients with type 1 diabetes and poor glycemic control (HbA1c above 9%) showed reduced final adult height compared to well-controlled peers [9]. Conversely, excessive weight gain during intensified insulin therapy may signal overbasalization, particularly if accompanied by recurrent hypoglycemia. In adolescents on degludec, unexplained weight gain with frequent lows should prompt a basal dose reduction and re-evaluation of the basal-bolus ratio.

Track Tanner staging at least annually. Pubertal progression directly predicts insulin requirement changes. Early puberty (Tanner 2 to 3) often triggers the steepest rise in insulin resistance, and the clinician should proactively increase the degludec dose by 10 to 15% rather than reacting to deteriorating HbA1c after the fact.

Dr. Lori Laffel, Chief of the Pediatric, Adolescent and Young Adult Section at Joslin Diabetes Center, has noted: "Proactive insulin dose adjustment during puberty, rather than reactive titration after glycemic deterioration, is the single most impactful clinical practice for adolescent outcomes" [10].

Thyroid and Autoimmune Comorbidity Screening

Approximately 17 to 30% of adolescents with type 1 diabetes have positive thyroid peroxidase (TPO) antibodies, and 5 to 10% develop overt autoimmune thyroid disease [11]. The ADA recommends screening with TSH shortly after type 1 diabetes diagnosis and then every 1 to 2 years, or sooner if symptoms arise [3].

Hypothyroidism can increase insulin requirements and worsen glycemic variability, mimicking inadequate basal insulin dosing. Before escalating the degludec dose in an adolescent with unexplained HbA1c rise, check TSH if it has not been tested in the past 12 months.

Screen for celiac disease with tissue transglutaminase IgA (tTG-IgA) shortly after diabetes diagnosis and consider repeat screening every 2 to 3 years or with symptoms. Undiagnosed celiac disease causes unpredictable carbohydrate absorption, making both basal and bolus insulin dosing erratic. This is relevant to degludec monitoring because the flat basal profile can mask the glycemic chaos of malabsorption, leading the clinician to overtitrate bolus insulin instead of identifying the underlying cause.

Psychosocial and Adherence Monitoring

Diabetes distress is not a secondary consideration. It is a primary driver of glycemic outcomes in adolescents. The SEARCH for Diabetes in Youth study found that 28% of adolescents with type 1 diabetes reported moderate-to-high diabetes distress, and distress scores correlated with HbA1c independent of treatment regimen [12].

Screen for diabetes distress using a validated instrument at least twice yearly. The Problem Areas in Diabetes-Teen (PAID-T) questionnaire is a practical tool that takes approximately 5 minutes to complete. A score above the clinical threshold should trigger a referral to a mental health provider with diabetes expertise.

Depression screening is separate from diabetes distress screening and equally necessary. The ISPAD 2022 guidelines recommend annual depression screening using the PHQ-A (Patient Health Questionnaire for Adolescents) starting at age 12 [7]. Depression reduces self-management behaviors, including CGM wear, injection site rotation, and carbohydrate counting, and these behavioral changes degrade glycemic control regardless of the insulin used.

Adherence to once-daily degludec is generally easier than twice-daily detemir or NPH, but "once daily" still means every day. A 2021 real-world study in Diabetes, Obesity and Metabolism found that among pediatric patients switching from glargine to degludec, treatment satisfaction improved significantly (DTSQc mean score 10.2, p<0.001), partly because degludec's flexible dosing window (up to 8 hours from the usual time) accommodated irregular adolescent schedules [13].

Ask about missed doses at every visit. A question like "In the past two weeks, how many degludec doses did you miss or take more than 8 hours late?" gives more actionable data than "Are you taking your insulin?" Smartphone reminders, pen-cap timers (such as Timesulin or InsulCheck), and parent-shared CGM data can support adherence without undermining the adolescent's developing autonomy.

Dr. Korey Hood, Professor of Pediatrics and Psychiatry at Stanford University School of Medicine, has stated: "The transition from parent-managed to self-managed diabetes during adolescence is where most glycemic deterioration occurs. Monitoring frameworks must address the handoff of responsibility, not just the biology" [14].

Injection Site Assessment and Lipohypertrophy

Examine injection sites at every visit. Lipohypertrophy occurs in approximately 40 to 50% of pediatric patients who inject insulin, and injection into lipohypertrophic tissue reduces insulin absorption by up to 25%, causing unpredictable glucose swings [15]. This is particularly problematic with a long-acting insulin like degludec because the effect of impaired absorption extends across the full 24-hour dosing interval.

Teach adolescents a systematic rotation pattern. The abdomen and thighs are the preferred sites for basal insulin. Each injection should be at least 1 cm from the previous site. Using a rotation grid drawn on the skin with a washable marker can help younger adolescents develop the habit.

If lipohypertrophy is detected, the switch to unaffected tissue may transiently increase insulin absorption, raising hypoglycemia risk. Reduce the degludec dose by 10 to 20% when redirecting injections away from hypertrophic sites, and retitrate based on fasting glucose over the following 1 to 2 weeks.

Laboratory Monitoring Schedule

Beyond HbA1c, a structured lab panel supports comprehensive monitoring:

Every 3 months: HbA1c (point-of-care preferred), CGM download review.

Every 6 months: Fasting lipid panel for adolescents aged 12 and older if previous values were abnormal; urine albumin-to-creatinine ratio (UACR) beginning after 5 years of diabetes duration or at puberty onset (whichever is earlier) per ADA Standards of Care [3].

Annually: TSH (autoimmune thyroid screening), dilated eye examination starting at age 11 with 2 to 5 years diabetes duration (or age 9 with more than 5 years duration), comprehensive metabolic panel including creatinine, and celiac screening if prior results were negative and symptoms are absent.

At each visit: Blood pressure, height, weight, BMI percentile, injection site examination, and psychosocial check-in.

The Endocrine Society Clinical Practice Guideline on managing type 1 diabetes emphasizes that adolescents require more frequent complication screening than the standard adult timeline because puberty accelerates microvascular risk accumulation [16]. Retinal screening should not be deferred until age 18 simply because the patient "seems too young."

When to Escalate or Refer

Refer to a pediatric endocrinologist (if not already managing the patient) when HbA1c exceeds 9.0% for two consecutive visits despite dose optimization and adherence support. Consider referral to a mental health professional specializing in chronic illness when diabetes distress or depression screening scores are elevated, when the adolescent expresses a desire to stop treatment, or when family conflict about diabetes management is recurrent.

Consider switching from degludec to an insulin pump if the adolescent has persistent dawn phenomenon unresponsive to dose increases, frequent activity-related hypoglycemia requiring variable basal rates, or strong patient preference for pump therapy. The switch from degludec to a pump requires a washout plan: because of the 25-hour half-life, overlap the pump's basal delivery with the last degludec injection by starting the pump at approximately 50% of the programmed basal rate for the first 12 hours, then increasing to full rate.

Adolescents aged 12 to 17 on Tresiba should have HbA1c measured every 3 months, CGM data reviewed at and between visits, injection sites examined for lipohypertrophy at each appointment, growth velocity plotted on standardized charts, thyroid function tested annually, and diabetes distress screened with a validated tool at least twice per year.